<DOC>
	<DOCNO>NCT00699777</DOCNO>
	<brief_summary>This study randomize , open-label , crossover study assess bioequivalence 1 risedronate 150 mg tablet versus 2 risedronate 75 mg tablet administer single oral dose . Approximately 320 subject enrol 4 study center U.S .</brief_summary>
	<brief_title>Assess Bioequivalence One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets Healthy Subjects</brief_title>
	<detailed_description>The data support interchangeability one risedronate 150 mg tablet versus two risedronate 75 mg tablet monthly dose form primarily base similarity vitro dissolution vivo study , show risedronate absorption dissolution rate limit . These result suggest monthly dose risedronate may accomplish administration either one risedronate 150 mg tablet two risedronate 75 mg tablet . The purpose study provide additional clinical data support interchangeability 2 dose regimen .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>good general health base medical history , physical examination , laboratory evaluation body mass index ( BMI ) â‰¤ 32 kg/m2 screen clinically significant uncontrolled cardiovascular , hepatic , renal , thyroid disease disease surgery know alter normal GI structure function creatinine clearance &lt; 60 mL/min , estimate serum creatinine use CockcroftGault formula</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>